Overview

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Status:
RECRUITING

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.

Phase:

PHASE3

Details

Lead Sponsor:

Hangzhou Sumgen Biotech Co., Ltd.

Treatments:

Dexamethasone
pomalidomide